Actionable Biomarkers in Acute Exacerbations of COPD: Corticosteroid and Antibiotic Stewardship.
- 1Department of Respiratory and Critical Care Medicine, The First Hospital of China Medical University, Shenyang, Liaoning, 110001, People's Republic of China.
- 2Day Surgery Ward, The First Hospital of China Medical University, Shenyang, Liaoning, 110001, People's Republic of China.
Abstract
Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) arise from heterogeneous inflammatory and infectious processes, yet systemic corticosteroids and antibiotics are often prescribed empirically. This narrative review evaluates biomarkers according to the acute treatment decisions they can support, drawing on randomized trials and supporting clinical studies evaluated through August 9, 2026. Blood eosinophils have the most developed evidence for corticosteroid guidance: trials support treatment selection or withholding in primary care and serial treatment shortening after an initial dose in hospitalized patients. C-reactive protein supports antibiotic stewardship most clearly in primary care, with more limited inpatient evidence. Procalcitonin can reduce antibiotic use in selected non-intensive-care inpatients, whereas the intensive-care trial failed to establish non-inferiority for mortality and did not reduce antibiotic exposure. These findings depend on the tested population, sampling time, threshold, and treatment rule. Rapid molecular pathogen tests improve diagnostic yield and turnaround time; their integration into COPD-specific treatment algorithms remains a research priority. Multimarker strategies and acute biologic treatment offer further avenues for investigation, with acute biologic evidence currently derived from a mixed asthma/COPD population. Organizing evidence around a biomarker-decision-population framework separates established stewardship applications from emerging treatment strategies. Clinical utility ultimately depends on whether the complete strategy preserves or improves patient outcomes and can be delivered reliably in routine care.
Related
- Corticosteroid Responsiveness Following COPD Exacerbations with Respiratory Failure
- Rational Corticosteroid Use: An Evidence-Based Narrative Review of Steroid Stewardship to Enhance Patient Safety Across Healthcare Settings.
- Improving Antibiotic Stewardship Through a Retrospective Study of the Diagnostic Value of Nasal Methicillin-Resistant Staphylococcus aureus Polymerase Chain Reaction for Pneumonia in Intensive Care Unit Settings
- Antibiotic Stewardship in Cirrhosis: Current Recommendations and Clinical Challenges
- Antibiotic-Refractory Fever with Pyelonephritis-like Features Revealing Occult Metastatic High-Grade Serous Carcinoma: Competing Causes of Fever and Diagnostic Stewardship
BibTeX
@article{li2026actionable,
title = {{Actionable Biomarkers in Acute Exacerbations of COPD: Corticosteroid and Antibiotic Stewardship.}},
author = {Yang Li and Yang Li},
journal = {International journal of chronic obstructive pulmonary disease},
year = {2026},
month = oct,
doi = {10.2147/copd.s649646},
url = {https://europepmc.org/article/MED/42968937},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Actionable Biomarkers in Acute Exacerbations of COPD: Corticosteroid and Antibiotic Stewardship.
AU - Yang Li
AU - Yang Li
PY - 2026
DA - 2026/10/28
JO - International journal of chronic obstructive pulmonary disease
DO - 10.2147/copd.s649646
UR - https://europepmc.org/article/MED/42968937
AB - Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) arise from heterogeneous inflammatory and infectious processes, yet systemic corticosteroids and antibiotics are often prescribed empirically. This narrative review evaluates biomarkers according to the acute treatment decisions they can support, drawing on randomized trials and supporting clinical studies evaluated through August 9, 2026. Blood eosinophils have the most developed evidence for corticosteroid guidance: trials support treatment selection or withholding in primary care and serial treatment shortening after an initial dose in hospitalized patients. C-reactive protein supports antibiotic stewardship most clearly in primary care, with more limited inpatient evidence. Procalcitonin can reduce antibiotic use in selected non-intensive-care inpatients, whereas the intensive-care trial failed to establish non-inferiority for mortality and did not reduce antibiotic exposure. These findings depend on the tested population, sampling time, threshold, and treatment rule. Rapid molecular pathogen tests improve diagnostic yield and turnaround time; their integration into COPD-specific treatment algorithms remains a research priority. Multimarker strategies and acute biologic treatment offer further avenues for investigation, with acute biologic evidence currently derived from a mixed asthma/COPD population. Organizing evidence around a biomarker-decision-population framework separates established stewardship applications from emerging treatment strategies. Clinical utility ultimately depends on whether the complete strategy preserves or improves patient outcomes and can be delivered reliably in routine care.
SN - 1176-9106
SN - 1178-2005
ER -